Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003). // Med. – URL: https://www.sciencedirect.com/science/article/pii/S2666634026002965?dgcid=rss_sd_all
Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003). Med. https://www.sciencedirect.com/science/article/pii/S2666634026002965?dgcid=rss_sd_all
“Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003).” Med.
@article{article58196,
title = {Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003)},
journal = {Med},
url = {https://www.sciencedirect.com/science/article/pii/S2666634026002965?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...